Proteomics International Laboratories (PIQ) AGM 2025 presentation summary

Commercial strategy and product pipeline

• Launching four first-in-class diagnostic tests in 2025: PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx, targeting major diseases with significant unmet needs and validated in large clinical studies.

• Tests offer significant advantages over current standards, including non-invasive procedures, higher accuracy, and earlier detection, with strong intellectual property protection and regulatory pathways established.

• Commercial platform and digital infrastructure built to drive awareness and adoption, with direct-to-GP and patient-driven strategies in Australia and the USA.

• Strategic focus on licensing, partnerships, and optionality for future revenue streams, leveraging a robust platform for global expansion.

• Highly experienced management and commercialisation team with proven track records in biotech, diagnostics, and global market access.

Financial and operational highlights

• Market capitalisation of A$52m as of November 2025, with A$12.7m in cash and a recent A$12m capital raise to fund launch strategies.

• Revenue-generating bioanalytical services help offset cash burn, with quarterly cash receipts of A$1.8m and cash burn of A$1m in Q1 FY26.

• Gross margins for diagnostic tests exceed 70%, with initial US pricing for PromarkerD at US$391 and PromarkerEndo/PromarkerEso estimated at US$1,000–1,500.

• Accredited laboratories in Australia (ISO 15189, 13485, 17025) and a CLIA-certified reference lab in California support clinical testing and commercial rollout.

Market opportunity and clinical validation

• Addressing large global markets: 537m adults with diabetes, 190m women with endometriosis, and 67m people with GERD in the USA alone.

• PromarkerD predicts diabetic kidney disease up to four years before symptoms, outperforming standard-of-care tests and enabling early intervention.

• PromarkerEndo and PromarkerEso demonstrate high sensitivity and specificity in large, multi-cohort clinical studies, with non-invasive blood tests for endometriosis and esophageal cancer.

• OxiDx offers a patented, field-ready blood test for oxidative stress, with applications in sports and veterinary medicine, and is nearing commercialisation.